

Review

Not peer-reviewed version

Advancements in Liposomal Drug Delivery Systems and Their Therapeutic Applications

[Ashutosh Sengar](#) *

Posted Date: 20 March 2025

doi: 10.20944/preprints202503.1540.v1

Keywords: liposomal drug delivery; nanocarriers; targeted therapy; controlled drug release; pharmaceutical nanotechnology



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Review

Advancements in Liposomal Drug Delivery Systems and Their Therapeutic Applications

Ashutosh Sengar

Assistant Professor, Dept. of Pharmaceutics, Smt. Vidyawati College of Pharmacy, Smt. Vidyawati Group of Institutions, Jhansi (U. P.), ashutoshsengar26567@gmail.com

Abstract: Liposomal drug delivery systems are a novel phenomenon in pharmaceutical sciences with increased bioavailability of the drug, reduced toxicity, and targeted delivery. Historical perspective of liposomes, constitution, and classification are discussed in this paper. Encapsulation mechanisms, loading efficiency, and controlled release are examined in relation to parameters that affect retention of the drug and therapeutic response. Stealth liposomes, nanocarriers, and regulation are discussed to highlight their evolving role in contemporary medicine. Therapeutic uses of liposomal products for cancer chemotherapy, treatment of infectious diseases, and antibiotics delivery are discussed, and how their site-specific action and capacity to overcome drug resistance render them promising. At the same time, in spite of all these advantages, some limitations in terms of stability issues, complexity of production on a large scale, and regulatory issues still restrict widespread clinical application. The paper outlines novel alternatives and solutions, which are written as polymer-coated liposomes and hybrid lipid systems, that have been designed to address the stability issue and scalability issue. With continuous innovations, liposomal drug delivery will be the focus of personalized medicine and targeted therapy. Resolution of current limitations by the aid of advanced nanotechnological techniques and regulatory improvements will be key to the realization of the true potential of liposomal formulations. This review is a detailed overview of current developments, challenges, and future directions of liposomal drug delivery, making it the focus of contemporary pharmaceutical science.

Keywords: liposomal drug delivery; nanocarriers; targeted therapy; controlled drug release; pharmaceutical nanotechnology

1. Introduction to Liposomal Drug Delivery Systems

Liposomal drug delivery systems emerged as a new trend in pharmaceutical sciences with improved therapeutic efficacy and targeted drug delivery. Liposomes are spherical, bilayered vesicles that can be used for the entrapment of lipophilic or hydrophilic drugs with enhanced bioavailability and reduced systemic toxicity [1]. Their phenomenal ability to increase drug solubility, prolong circulation half-life, and deliver drugs at the site has made them part of a construct of advanced nanomedicine [2].

1.1. Evolution and Historical Significance of Liposomes in Drug Delivery

Liposomes were first suggested to be synthesized in the 1960s by Alec Bangham through his serendipitous discovery of their bilayer nature while experimenting with phospholipids. Scientists tested them for delivering drugs through the next few decades, which eventually led to the first FDA-approved liposomal drug, Doxil®, in the 1990s [1]. Liposomes have a history of centuries and are distinguished by the cyclic development of stability, targeting capacity, and industrial manufacturability and thus are a drug carrier option for chemotherapy, antifungal agents, and vaccines [2].

1.2. Basic Structure, Composition, and Classification of Liposomes

Liposomes are made up of cholesterol and phospholipid molecules which when arranged form vesicles to transport therapeutic agents. Their structure determines their permeability, stability, and capacity to interact with biological membranes. Structurally, liposomes belong to the category of multilamellar vesicles and small and large unilamellar vesicles and possess farraginous applications as drug-delivery vehicles [3]. Multidimensional physicochemical properties, such as charge, size, and surface ornamentation, regulate their in vivo fate and immune system perception for clearance [4]. Moreover, liposomes have been classified as functionally altered in the context of such manipulations as stealth liposomes, cationic liposomes, and immunoliposomes, which are of some therapeutic interests [5].

2. Mechanisms of Liposomal Drug Encapsulation and Release

Liposomal drug delivery systems rely on efficient drug encapsulation and programmed release processes for maximum therapeutic effect. Liposomes can trap hydrophilic and lipophilic drugs in the forms of increased bioavailability and targeted release. Drug loading capacity and rate of release are controlled by numerous factors, including encapsulation type, lipid matrix, and environmental conditions [6].

2.1. Methods of Drug Loading and Encapsulation Efficiency

There are passive or active methods by which drugs can be loaded into liposomes. Ethanol injection and thin-film hydration are some of the passive loading techniques by which the drug becomes entrapped during vesicle formation. These techniques give low encapsulation efficiency [6]. Whereas active loading procedures, such as pH gradient and ion gradient treatments, enhance entrapment of drugs by providing a chemical gradient along which drug molecules are pushed into liposomes, significantly improving loading efficiency [7]. The stability of drugs, release rates, and bioactivity are influenced by the type of process to be employed.

2.2. Controlled Release Mechanisms and Factors Influencing Drug Release

Released drugs by liposomes are controlled by the lipid structure, vesicle dimensions, and an external stimulus. Release is regulated by diffusion, breakdown of lipids, or by external stimuli like pH, temperature, and ultrasound [8]. For instance, pH-sensitive liposomes release the payload at low pH and are therefore best for targeting cancer cells [9]. In addition, liposomes are formulated to release drugs in response to hyperthermia, thereby providing effective and targeted drug delivery [10]. Mechanistic insight optimizes liposomal preparation to perform long-term and targeted therapeutic action.

3. Advancements in Liposomal Drug Delivery Systems

Current developments in drug liposomal delivery systems have concentrated on advancing stability, targeted delivery, and clinical usage. Advances in stealth liposomes and newer nanocarriers have optimized drug efficacy while minimizing side effects to a greater extent. Innovative strategies overcome intrinsic limitations of drug delivery, including increased immune system clearance and tissue non-specific distribution [11].

Table 1. Advancements in Liposomal Drug Delivery Systems.

Advancement	Description	Reference
Stealth Liposomes	PEGylation reduces immune system recognition, prolonging circulation time	[11]

Targeted Liposomal Delivery	Functionalized with ligands (e.g., antibodies, folate) for precise tissue targeting	[11]
Nanocarrier Innovations	Hybrid liposomes with polymer coatings improve drug stability and release control	[11]
Overcoming Immune Clearance	Surface modifications (e.g., zwitterionic coatings) reduce opsonization	[11]
Reducing Non-Specific Distribution	Controlled drug release strategies improve therapeutic index and minimize off-target effects	[11]

3.1. *Innovations in Stealth Liposomes and Targeted Delivery*

Stealth liposomes have been made to escape MPS recognition with an increased circulation half-life and improved drug deposition within target tissues. This can be achieved by PEGylation of liposomes, which forms a hydrophilic coating that protects them from opsonization and immune-mediated destruction [12]. Site-specific liposomal formulations also incorporate ligands like monoclonal antibodies, peptides, and aptamers to target the drug to a site, e.g., cancer and inflammatory diseases [11]. Targeted drug delivery systems minimize therapeutic intervention as well as diminished systemic toxicity.

3.2. *Next-Generation Nanocarriers and Regulatory Considerations*

Liposome technology has been advanced with next-generation nanocarriers like hybrid liposomes, stimulus-responsive vesicles, and multistage/multifunctional preparations. Hybrid liposomes have embraced polymers or inorganic nanoparticles for the purpose of adding extra stability along with drug-controlled release [13]. Stimuli-responsive liposomes are made to deliver drugs based on certain stimuli like pH level change, temperature variation, or enzymatic activity and are therefore extremely promising for precision medicine [14]. Concerns of a regulatory nature for such new liposomal drugs include safety, scalability, and reproducibility of production for meeting international pharmaceutical standards before use in the clinic [15].

4. **Therapeutic Applications of Liposomes in Medicine**

Drug delivery by liposomes has revolutionized therapy in the majority of the fields of therapy with improved bioavailability, site specificity, and reduced toxicity. Liposomal drugs are widely utilized in cancer treatment, infectious diseases treatment, and antibiotic treatment with improved pharmacokinetics and therapeutic efficacy relative to their non-liposomal drug counterparts [16].

4.1. *Liposomal Formulations in Cancer Therapy and Infectious Diseases*

Liposomal delivery has changed cancer therapy by improving drug residence in tumors and reducing systemic toxicity. A prototypic example is pegylated liposomal doxorubicin (Doxil®), which exhibits prolonged circulation half-life and tumor-preferential uptake, increased efficacy, and reduced toxicity [17]. Liposomal carriers have also been applied to antifungal and antiviral therapies for drug solubilization and improved bioavailability for infectious diseases such as leishmaniasis and fungal infections [16].

4.2. *Use of Liposomes in Antibiotic Delivery and Overcoming Resistance*

Entrapment by liposomal increases the efficacy of antibiotics by the shielding effect against enzymatic degradation, augmented penetration into biofilms, and reduced chances of resistance evolution.

As an example, liposome entrapping fluoroquinolones and aminoglycosides was claimed to possess enhanced pharmacokinetics with reduced nephrotoxicity [18]. Targeted liposomal antibiotics are also effective in the eradication of drug-resistant bacterial infection through the enablement of retention of the drug at the infection site and lessening off-target toxicity [19]. Liposome technology is being utilized in the use of antibiotics on a day-to-day basis in order to address the escalating threat of antimicrobial resistance [20].

Table 2. Therapeutic Applications of Liposomal Drug Delivery.

Therapeutic Area	Liposomal Drug Example	Key Benefits	Reference
Cancer Therapy	Doxil® (Pegylated Liposomal Doxorubicin)	Prolonged circulation, tumor-specific uptake, reduced toxicity	[17]
Infectious Diseases	AmBisome® (Liposomal Amphotericin B)	Improved bioavailability, lower nephrotoxicity for fungal infections	[16]
Antiviral Therapy	Liposomal Acyclovir	Enhanced drug solubility and controlled release	[16]
Antibiotic Delivery	Liposomal Fluoroquinolones & Aminoglycosides	Protection from enzymatic degradation, reduced nephrotoxicity	[18]
Drug-Resistant Bacterial Infections	Targeted Liposomal Antibiotics	Localized drug retention, lower off-target toxicity, overcoming resistance	[19]
Antimicrobial Resistance	Liposomal Antibiotics (Various)	Enhancing efficacy of existing antibiotics to counter resistance	[20]

5. Challenges and Limitations in Liposomal Drug Delivery

While there are a number of benefits that can be ascribed to liposomal drug delivery, there are certain limitations to its clinic application in all cases. They are stability, scalability, and manufacturing limitations. Overcoming these limitations is the focus of research on liposomal drug delivery technologies currently [21].

5.1. Stability, Scalability, and Manufacturing Constraints

Liposomal preparations are also plagued by stability since phospholipid bilayers are susceptible to degradation by reactions such as oxidation, hydrolysis, and drug encapsulated within them being lost, resulting in drug entrapment and loss of activity [22]. Bulk production of liposomes also involves very strict control over particle size, encapsulation efficiency, and sterilization and is therefore difficult and costly to make [21].

5.2. Future Prospects and Potential Solutions for Overcoming Limitations

Nanotechnology and lipid drug delivery technology are attempting to address some of these issues with enhanced liposome stability through polymer-coated and hybrid lipid formulations [23]. In addition to that, regulatory policy reform is also underway to establish streamlined approval processes for new liposomal products so that they may be launched on the market [24]. Science is continuously discovering new methods, such as stimulus-responsive liposomes and multifunctional nanocarriers, to further enhance therapeutic result and extend use of liposomes in medicine [25].

6. Conclusion

Liposomal drug delivery systems have transformed routine pharmacology with improved bioavailability of drugs, decreased toxicity, and selective drug delivery to the action site. Since their evolutionary beginning, liposomes have evolved as multifunctional drug carriers for various therapeutic usages. The different modes of drug loading and controlled release mechanisms are responsible for their effectiveness, and the advancements that have been realized in stealth liposomes and second-generation nanocarriers are continuously enhancing their efficacy.

Liposomal products have also demonstrated unparalleled efficacy in cancer, infectious disease, and antibiotic therapy treatment by circumventing drug resistance and site-specific targeting restrictions. Though there are many benefits, stability, scalability, and regulatory challenges are present limitations. Nanotechnology advances, hybrid lipid systems, and regulatory guideline advances are progressively supplanting these limitations with continuing liposomal therapeutic development.

The more research is undertaken, the more liposomes will be a pillar of precision medicine with even stronger and less side effect-prone drugs in most areas of practice of medicine. Overcoming their current limitations through new technology will even provide even greater impetus to their therapeutic uses, as liposomal drug delivery becomes the foundation of the science of drugs in the current age.

References

1. Torchilin, V. P. (2005). Liposomes as pharmaceutical carriers. *Nature Reviews Drug Discovery*, 4(2), 145–160. <https://doi.org/10.1038/nrd1632>
2. Lasic, D. D. (1998). Novel applications of liposomes. *Trends in Biochemical Sciences*, 23(11), 444–449. [https://doi.org/10.1016/S0968-0004\(98\)01270-0](https://doi.org/10.1016/S0968-0004(98)01270-0)
3. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013). Liposome: Classification, preparation, and applications. *Nanoscale Research Letters*, 8, 102. <https://doi.org/10.1186/1556-276X-8-102>
4. Laouini, A., Jaafar-Maalej, C., Limayem-Blouza, I., Sfar, S., Charcosset, C., & Fessi, H. (2012). Preparation, characterization and applications of liposomes: State of the art. *Journal of Colloid Science and Biotechnology*, 1(2), 147–168. <https://doi.org/10.1166/jcsb.2012.1020>
5. Kulkarni, P. R., Yadav, J. D., & Vaidya, K. A. (2011). Liposomes: A novel drug delivery system. *International Journal of Current Pharmaceutical Research*, 3(2), 10–18.
6. Samad, A., Sultana, Y., & Aqil, M. (2007). Liposomal drug delivery systems: An update review. *Current Drug Delivery*, 4(4), 297–305. <https://doi.org/10.2174/156720107782151269>
7. Choudhury, A., Sonowal, K., Laskar, R. E., Deka, D., & Dey, B. K. (2020). Liposome: A carrier for effective drug delivery. *Journal of Applied Pharmaceutical Research*, 8(1), 22–28. <https://doi.org/10.18231/j.joapr.2019.v.8.i.1.003>

8. Farooque, F., Wasi, M., & Mughees, M. M. (2021). Liposomes as drug delivery system: An updated review. *Journal of Drug Delivery and Therapeutics*, 11(5-S), 149–158. <https://doi.org/10.22270/jddt.v11i5-S.5063>
9. Daraee, H., Etemadi, A., Kouhi, M., Alimirzalu, S., & Akbarzadeh, A. (2016). Application of liposomes in medicine and drug delivery. *Artificial Cells, Nanomedicine, and Biotechnology*, 44(1), 381–391. <https://doi.org/10.3109/21691401.2014.953633>
10. Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007). Bioavailability of curcumin: Problems and promises. *Molecular Pharmaceutics*, 4(6), 807–818. <https://doi.org/10.1021/mp700113r>
11. Sercombe, L., Veerati, T., Moheimani, F., Wu, S. Y., Sood, A. K., & Hua, S. (2015). Advances and challenges of liposome-assisted drug delivery. *Frontiers in Pharmacology*, 6, 286. <https://doi.org/10.3389/fphar.2015.00286>
12. Immordino, M. L., Dosio, F., & Cattel, L. (2006). Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. *International Journal of Nanomedicine*, 1(3), 297–315. <https://doi.org/10.2147/IJN.S10112>
13. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36–48. <https://doi.org/10.1016/j.addr.2012.09.037>
14. Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017). Liposomal formulations in clinical use: An updated review. *Pharmaceutics*, 9(2), 12. <https://doi.org/10.3390/pharmaceutics9020012>
15. Sengar, A. (2025). Next-generation liposomal drug delivery systems: Core principles, innovations, and targeting strategies. *Preprints*. <https://doi.org/10.20944/preprints202501.1875.v1>
16. Sengar, A., Chatekar, V. K., Andhare, S. B., & Sharma, L. (2025). Clinical pharmacology of antibiotics: Mechanisms, therapeutic uses, and resistance patterns. *World Journal of Pharmaceutical Research*, 14(1), 1531–1545. <https://doi.org/10.20959/wjpr20251-35216>
17. Gabizon, A., & Papahadjopoulos, D. (1988). Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. *Proceedings of the National Academy of Sciences*, 85(18), 6949–6953. <https://doi.org/10.1073/pnas.85.18.6949>
18. Sengar, A. (2025). Targeting strategies in liposomal drug delivery. *Preprints*. <https://doi.org/10.20944/preprints202501.0866.v1>
19. Mansoori, M. A., Agrawal, S., Jawade, S., & Khan, M. I. (2012). A review on liposome. *International Journal of Advanced Research in Pharmaceutical & Bio Sciences*, 2(4), 453–464.
20. Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. *Journal of Controlled Release*, 160(2), 117–134. <https://doi.org/10.1016/j.jconrel.2012.03.010>
21. Sengar, A. (2025). Innovations and mechanisms in liposomal drug delivery: A comprehensive introduction. *Preprints*. <https://doi.org/10.20944/preprints202501.0206.v1>
22. Sengar, A., et al. (2025). Advancing urolithiasis treatment through herbal medicine: A focus on Tribulus terrestris fruits. *World Journal of Pharmaceutical Research*, 14(2), 91–105.
23. Immordino, M. L., Dosio, F., & Cattel, L. (2008). Nanocarriers as an emerging platform for cancer therapy. *European Journal of Pharmaceutics and Biopharmaceutics*, 68(3), 291–300. <https://doi.org/10.1016/j.ejpb.2007.10.005>
24. Zylberberg, C., & Matosevic, S. (2016). Pharmaceutical liposomal drug delivery: A review of new delivery systems and a look at the regulatory landscape. *Drug Delivery*, 23(9), 3319–3329. <https://doi.org/10.1080/10717544.2016.1177136>
25. Maheswaran, A., Brindha, P., Mullaicharam, A. R., & Masilamani, K. (2013). Liposomal drug delivery systems – A review. *International Journal of Pharmaceutical Sciences Review and Research*, 21(1), 62–69.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.